Artivion, Inc.
A maker of cardiac and vascular medical devices and preserved human tissues, Artivion helps surgeons treat aortic disease with products like the On-X mechanical heart valve, BioGlue surgical sealant, and aortic stent grafts, while its cryopreservation service banks donated heart valves and blood vessels. It began in 1984 as CryoLife, founded by Steven Anderson and Robert McNally as the first company to specialize in freezing human heart valves. In 2022 it renamed itself Artivion, a blend of "aorta," "innovation," and "vision."
Granted 841.6K · Sold 446.2K
Granted 198.2K · Sold 98.1K
Granted 240.0K · Sold 29.1K
Granted 233.0K · Sold 182.8K
Granted 20.2K
Granted 20.2K
Granted 106.0K · Sold 71.0K
Granted 20.2K
Granted 13.9K · Bought 2.1K · Sold 12.3K
Granted 69.0K · Sold 61.0K
Granted 20.2K
Granted 20.2K
Granted 167.6K · Sold 160.9K
Granted 20.2K
Granted 21.3K · Sold 4.2K
Granted 6.5K · Sold 1.5K
Granted 23.6K · Sold 19.9K
Granted 20.2K · Sold 4.2K
Granted 8.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Mackin James PPresident & CEO · 34 transactions | +71.6% | 947.3K | 841.6K | — | 446.2K |
| Davis John EChief Commercial Officer · 38 transactions | +76.5% | 230.8K | 198.2K | — | 98.1K |
| Berry Lance AEVP, COO, CFO & Treasurer · 12 transactions | — | 210.8K | 240.0K | — | 29.1K |
| Holloway Jean FSVP, General Counsel · 58 transactions | +37.2% | 185.1K | 233.0K | — | 182.8K |
| Bevevino Daniel JDirector · 3 transactions | +14.7% | 157.6K | 20.2K | — | — |
| Ackerman Thomas FDirector · 3 transactions | +14.7% | 157.5K | 20.2K | — | — |
| Horton AmyVP, Chief Accounting Officer · 39 transactions | +29.1% | 139.1K | 106.0K | — | 71.0K |
| Salveson Jon WDirector · 3 transactions | +17.2% | 137.4K | 20.2K | — | — |
| Semedo Anthony B.Director · 8 transactions | — | 94.5K | 13.9K | 2.1K | 12.3K |
| Green Andrew MSVP, Regulatory and Quality · 15 transactions | +253% | 90.3K | 69.0K | — | 61.0K |
| Bullock JamesDirector · 3 transactions | +36% | 76.2K | 20.2K | — | — |
| Burbank Jeffrey HDirector · 3 transactions | +49% | 61.4K | 20.2K | — | — |
| Stanton Marshall S.SVP, Clinical & MD Affair · 49 transactions | +12.7% | 60.1K | 167.6K | — | 160.9K |
| Borgstrom Marna PDirector · 3 transactions | +55.4% | 56.7K | 20.2K | — | — |
| Maney Rochelle L.VP, Quality · 9 transactions | +57.7% | 46.6Kas of Mar 2024 | 21.3K | — | 4.2K |
| Tyrs FlorianVP, Global Operations · 4 transactions | +18.7% | 42.6Kas of Feb 2024 | 6.5K | — | 1.5K |
| Getz Matthew AVP, Human Resources · 13 transactions | +20.7% | 36.7Kas of Aug 2024 | 23.6K | — | 19.9K |
| Hoff Elizabeth ADirector · 4 transactions | +85.2% | 34.8K | 20.2K | — | 4.2K |
| Thomson Robert CVP Research & Development · 1 transaction | +15.7% | 13.3Kas of Feb 2024 | 8.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.09M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.